P.A.W. Capital’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

P.A.W. Capital’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-14,000	Closed	-$1.12M	–	66
2019 Q3	$1.12M	Sell	14,000 -1,000	-7%	-$84.9K	1.4%	23
2019 Q2	$1.42M	Sell	15,000 -10,000	-40%	-$863K	1.53%	25
2019 Q1	$2.14M	Hold	25,000	–	–	2.11%	17
2018 Q4	$1.4M	Buy	25,000 +1,100	+5%	+$67.2K	1.76%	18
2018 Q3	$1.95M	Sell	23,900 -16,100	-40%	-$1.13M	2.07%	16
2018 Q2	$1.4M	Sell	40,000 -20,000	-33%	-$609K	1.41%	22
2018 Q1	$1.23M	Buy	60,000 +20,000	+50%	+$515K	1.48%	25
2017 Q4	$1.13M	Buy	40,000 +10,000	+33%	+$279K	1.43%	25
2017 Q3	$933K	Buy	+30,000	New	+$902K	0.98%	45

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

P.A.W. Capital's RETA Position: Q4 2019 in Review

P.A.W. Capital sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2019, closing a stake of 14,000 shares — an estimated $1.12M sold.

P.A.W. Capital first reported a position in RETA in Q3 2017 and held it in 9 quarters. The position peaked at $2.14M in Q1 2019. 218 funds tracked by Wall St. Rank hold RETA as of Q4 2019.

P.A.W. Capital reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2019 after selling out during the quarter.
P.A.W. Capital sold 14,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2019, an estimated $1.12M.
P.A.W. Capital first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 9 quarters.
P.A.W. Capital's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.14M in Q1 2019.
218 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2019.

Based on P.A.W. Capital's 13F filing for Q4 2019, filed 28 Jan 2020.